IL278596B2 - RAS oncoprotein inhibitors, methods for preparing and methods for using them - Google Patents

RAS oncoprotein inhibitors, methods for preparing and methods for using them

Info

Publication number
IL278596B2
IL278596B2 IL278596A IL27859620A IL278596B2 IL 278596 B2 IL278596 B2 IL 278596B2 IL 278596 A IL278596 A IL 278596A IL 27859620 A IL27859620 A IL 27859620A IL 278596 B2 IL278596 B2 IL 278596B2
Authority
IL
Israel
Prior art keywords
alkyl
alkoxy
aryl
compound
alkenyl
Prior art date
Application number
IL278596A
Other languages
English (en)
Hebrew (he)
Other versions
IL278596B1 (en
IL278596A (cg-RX-API-DMAC7.html
Original Assignee
Univ Louisville Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found Inc filed Critical Univ Louisville Res Found Inc
Publication of IL278596A publication Critical patent/IL278596A/en
Publication of IL278596B1 publication Critical patent/IL278596B1/en
Publication of IL278596B2 publication Critical patent/IL278596B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL278596A 2018-05-10 2019-05-10 RAS oncoprotein inhibitors, methods for preparing and methods for using them IL278596B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862669926P 2018-05-10 2018-05-10
PCT/US2019/031885 WO2019217933A1 (en) 2018-05-10 2019-05-10 Inhibitors of the ras oncoprotein, methods of making and methods of use thereof

Publications (3)

Publication Number Publication Date
IL278596A IL278596A (cg-RX-API-DMAC7.html) 2020-12-31
IL278596B1 IL278596B1 (en) 2025-01-01
IL278596B2 true IL278596B2 (en) 2025-05-01

Family

ID=68467113

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278596A IL278596B2 (en) 2018-05-10 2019-05-10 RAS oncoprotein inhibitors, methods for preparing and methods for using them

Country Status (10)

Country Link
US (2) US12582660B2 (cg-RX-API-DMAC7.html)
EP (1) EP3790541B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021528368A (cg-RX-API-DMAC7.html)
KR (1) KR20210009331A (cg-RX-API-DMAC7.html)
CN (1) CN112312901B (cg-RX-API-DMAC7.html)
AU (1) AU2019265011B2 (cg-RX-API-DMAC7.html)
CA (1) CA3099148A1 (cg-RX-API-DMAC7.html)
IL (1) IL278596B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020011991A (cg-RX-API-DMAC7.html)
WO (1) WO2019217933A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011991A (es) 2018-05-10 2021-04-12 Univ Louisville Res Found Inc Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CN117731785A (zh) * 2022-09-15 2024-03-22 上海交通大学医学院附属第九人民医院 一种用于治疗脉管畸形的载药乙醇可视化复合制剂及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064398A1 (en) * 1998-06-09 1999-12-16 Nortran Pharmaceuticals, Inc. Quarternary ammonium compounds as anti-tussive agents
US20080139534A1 (en) * 2006-12-07 2008-06-12 Xavier University Of Louisiana Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis
US20090124620A1 (en) * 2007-07-25 2009-05-14 Toshio Miyata Plasminogen activator inhibitor-1 inhibitor
WO2009080805A1 (en) * 2007-12-21 2009-07-02 Pierre Fabre Medicament Dimeric derivatives of artemisinin and application in anticancer therapy
WO2009136175A1 (en) * 2008-05-07 2009-11-12 Medical Research Council Compounds for use in stabilizing p53 mutants
WO2014037726A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Liquid pharmaceutical compositions
EP2759533A1 (en) * 2011-09-22 2014-07-30 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
US20180044314A1 (en) * 2014-12-16 2018-02-15 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233051A (ja) 1984-05-04 1985-11-19 Daicel Chem Ind Ltd ２−クロル−５−ニトロベンゼンスルホンアミドの製造方法
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
CN101919842A (zh) * 2009-06-11 2010-12-22 复旦大学 一种苯丙噻吩衍生物在制备抗肿瘤药物中的应用
WO2011103435A2 (en) 2010-02-18 2011-08-25 The Board Of Trustees Of The University Of Illinois Methods for forming protected organoboronic acids
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
KR20120048223A (ko) 2010-11-05 2012-05-15 주식회사 이큐스앤자루 2-페닐-4-[3-(치환된-설포닐)아닐리노]퀴나졸린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물
GB201020397D0 (en) * 2010-12-02 2011-01-12 Univ Nottingham Compounds
ES2491390B1 (es) * 2013-02-04 2015-06-22 Universidad Complutense De Madrid Nuevos inhibidores de la enzima isoprenilcisteina carboximetiltransferasa (icmt)
CN105283454B (zh) 2013-04-12 2019-10-29 阿萨纳生物科技有限责任公司 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用
MX2020011991A (es) 2018-05-10 2021-04-12 Univ Louisville Res Found Inc Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064398A1 (en) * 1998-06-09 1999-12-16 Nortran Pharmaceuticals, Inc. Quarternary ammonium compounds as anti-tussive agents
US20080139534A1 (en) * 2006-12-07 2008-06-12 Xavier University Of Louisiana Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis
US20090124620A1 (en) * 2007-07-25 2009-05-14 Toshio Miyata Plasminogen activator inhibitor-1 inhibitor
WO2009080805A1 (en) * 2007-12-21 2009-07-02 Pierre Fabre Medicament Dimeric derivatives of artemisinin and application in anticancer therapy
WO2009136175A1 (en) * 2008-05-07 2009-11-12 Medical Research Council Compounds for use in stabilizing p53 mutants
EP2759533A1 (en) * 2011-09-22 2014-07-30 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
WO2014037726A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Liquid pharmaceutical compositions
US20180044314A1 (en) * 2014-12-16 2018-02-15 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KACZOR AGNIESZKA A. ET AL,, STRUCTURE-BASED VIRTUAL SCREENING FOR DOPAMINE D 2 RECEPTOR LIGANDS AS POTENTIAL ANTIPSYCHOTICS, 18 March 2016 (2016-03-18) *
MILTON J ET AL,, BIARYL ACIDS: NOVEL NON-NUCLEOSIDE INHIBITORS OF HIV REVERSE TRANSCRIPTASE TYPES 1 AND 2, 6 October 1998 (1998-10-06) *

Also Published As

Publication number Publication date
JP2021528368A (ja) 2021-10-21
MX2020011991A (es) 2021-04-12
CN112312901A (zh) 2021-02-02
EP3790541B1 (en) 2024-12-04
JP2024056937A (ja) 2024-04-23
US20210137939A1 (en) 2021-05-13
WO2019217933A1 (en) 2019-11-14
KR20210009331A (ko) 2021-01-26
IL278596B1 (en) 2025-01-01
CN112312901B (zh) 2024-05-14
WO2019217933A8 (en) 2021-02-11
US20260232689A1 (en) 2026-08-13
EP3790541A4 (en) 2022-02-16
EP3790541A1 (en) 2021-03-17
IL278596A (cg-RX-API-DMAC7.html) 2020-12-31
AU2019265011A1 (en) 2020-11-26
CA3099148A1 (en) 2019-11-14
US12582660B2 (en) 2026-03-24
AU2019265011B2 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
US12234226B2 (en) Compounds as nuclear transport modulators and uses thereof
JP7058345B2 (ja) Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
IL278596B1 (en) RAS oncoprotein inhibitors, methods for preparing and methods for using them
IL267992B2 (en) Combination therapy involving macrocyclic diaryl compounds
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
IL278281B2 (en) Crystalline form of C–MET inhibitor and its salt form and method for preparing them
IL281348B1 (en) Combination of SHP-2 inhibitor and KRAS inhibitor G12C for cancer treatment
IL287558B2 (en) Method of screening for agents for differentiating stem cells
IL296091A (en) Inhibitors of braf, kras, egfr and other targets and their uses
IL296034A (en) Inhibitors of braf, kras, egfr and other targets and their uses
IL257306A (en) A compressed pyrimidine compound or its salt
CN101083996A (zh) 作为hedgehog途径调节剂的化合物和组合物
IL312120B1 (en) Medical preparation
CN115433187B (zh) 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
JP2022019812A (ja) ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
IL324314A (en) Egfr inhibitor for treating cancers comprising atypical egfr mutations
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
IL312896A (en) 15-PGDH inhibitor and its use
IL295938A (en) Therapeutic uses of macrocyclic compounds
CN103619331A (zh) 抗癌治疗剂
IL307739A (en) Nitrophenylacrylamides and their use
US11426371B2 (en) Compositions and methods for treating cancer
JP2021532188A (ja) μオピオイド受容体のアロステリックモジュレーター
WO2026044133A1 (en) Methods and compositions for the treatment of cancer
JP2018513192A (ja) Ｒａｃ−ＧＴＰアーゼ媒介性障害を処置するための化合物